Ersodetug
Congenital Hyperinsulinism
Key Facts
About Rezolute
Rezolute is a clinical-stage biotech focused on rare metabolic diseases, with its lead candidate, ersodetug, in two pivotal Phase 3 trials for congenital and tumor hyperinsulinism. The company's mission is to significantly improve the quality of life for patients and families affected by severe hypoglycemia. Despite a recent setback in its congenital HI trial, Rezolute is engaging with the FDA under Breakthrough Therapy Designation and continues to advance its tumor HI study, supported by a leadership team with deep expertise in rare disease drug development and commercialization.
View full company profileAbout Rezolute
Rezolute is a clinical-stage biotech focused on rare metabolic diseases, with its lead candidate, ersodetug, in two pivotal Phase 3 trials for congenital and tumor hyperinsulinism. The company's mission is to significantly improve the quality of life for patients and families affected by severe hypoglycemia. Despite a recent setback in its congenital HI trial, Rezolute is engaging with the FDA under Breakthrough Therapy Designation and continues to advance its tumor HI study, supported by a leadership team with deep expertise in rare disease drug development and commercialization.
View full company profileTherapeutic Areas
Other Congenital Hyperinsulinism Drugs
| Drug | Company | Phase |
|---|---|---|
| RM-718 | Rhythm Pharmaceuticals | Pre-clinical |
| XP-8121 | Xeris Pharmaceuticals | Preclinical/Phase 1 |
| XOMA 358 (RZ358) | XOMA | Phase 2 |